Yang Qundi – Trademark Portfolio

Entity Type: 01

Yang Qundi holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include DUSRINAB and GMBOKEEN. The owner is based in Maoming, Guangdong.

Room 401, No. 47, Kuangzhong Road

Maoming, Guangdong 525000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DUSRINAB
DUSRINAB
Registered 2021
GMBOKEEN
GMBOKEEN
Registered 2021

Trademark Classifications

Yang Qundi's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Yang Qundi have?

Yang Qundi has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Yang Qundi file in?

Yang Qundi files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are Yang Qundi's most well-known trademarks?

Yang Qundi's registered trademark portfolio includes well-known marks such as DUSRINAB and GMBOKEEN. These are among 2 currently registered trademarks in the portfolio.

What is Yang Qundi's trademark registration success rate?

Yang Qundi has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.